Nomogram to predict risk of resistance to intravenous immunoglobulin in children hospitalized with Kawasaki disease in Eastern China

References

• Lo MS, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21(1):64–69.
   PubMed Web of Science ®Google Scholar
• Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol. 2009;53(1):15–19.
   PubMed Web of Science ®Google Scholar
• Huang H, Xu L, Ding Y, et al. Bioinformatics identification of hub genes and signaling pathways regulated by intravenous immunoglobulin treatment in acute Kawasaki disease. Exp Ther Med. 2021;22(1):1–13.
   Web of Science ®Google Scholar
• Group J. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease. Pediatr Int. 2005;47(6):711–732.
   PubMed Web of Science ®Google Scholar
• Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128(1):146–149.
   PubMed Web of Science ®Google Scholar
• Ae R, Abrams JY, Maddox RA, et al. Corticosteroids added to initial intravenous immunoglobulin treatment for the prevention of coronary artery abnormalities in high-risk patients with Kawasaki disease. J Am Heart Assoc. 2020;9(17):e015308.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–2612.
   PubMed Web of Science ®Google Scholar
• Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–240.
   PubMed Web of Science ®Google Scholar
• Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2006;166(2):131–137.
   PubMed Web of Science ®Google Scholar
• Sleeper LA, Minich LL, McCrindle BM, Pediatric Heart Network Investigators, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831–835.
   PubMed Web of Science ®Google Scholar
• Son MBF, Gauvreau K, Kim S, et al. Predicting coronary artery aneurysms in Kawasaki disease at a North American center: an assessment of baseline z scores. JAHA. 2017;6(6):e005378.
   Google Scholar
• Tang Y, Yan W, Sun L, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an east China population. Clin Rheumatol. 2016;35(11):2771–2776.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young. American Heart Association. Circulation. 2004;110(17):2747–2771.
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Rowley AH, Newburger JW, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation. 2017;135(17):e927–e99.
   PubMed Web of Science ®Google Scholar
• Akagi T, Rose V, Benson LN, et al. Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr. 1992;121(5):689–694.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang L, Liu Z, et al. Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram. Patient Prefer Adherence. 2018;12:1757–1765. Volume
   PubMed Web of Science ®Google Scholar
• Wu J, Qiu J, Xie E, et al. Predicting in-hospital rupture of type a aortic dissection using random Forest. J Thorac Dis. 2019;11(11):4634–4646.
   PubMed Web of Science ®Google Scholar
• Kliegman RM, Stanton BM, Geme JS. Growth, development, and behavior. Nelson textbook of pediatrics. 20th ed. Elsevier; 2015. p. 52.
   Google Scholar
• Okada K, Hara J, Maki I, Osaka Kawasaki Disease Study Group, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168(2):181–185.
   PubMed Web of Science ®Google Scholar
• Yang S, Song R, Zhang J, et al. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing. Arch Dis Child. 2019;104(3):262–267.
   PubMed Web of Science ®Google Scholar
• Xie T, Wang Y, Fu S, et al. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease. Pediatr Rheumatol. 2017;15(1):17.
   PubMedGoogle Scholar
• Wei M, Huang M, Chen S, et al. A multicenter study of intravenous immunoglobulin non-response in Kawasaki disease. Pediatr Cardiol. 2015;36(6):1166–1172.
   PubMed Web of Science ®Google Scholar
• Sharma K, Vignesh P, Srivastava P, et al. Epigenetics in Kawasaki disease. Front Pediatr. 2021;9:673294.
   PubMed Web of Science ®Google Scholar
• Yuan P, Su D, Mandal KD, et al. Outcomes of Kawasaki disease with giant coronary aneurysms: a single-Centre study in southwest China. Cardiol Young. 2020;30(6):834–839.
   PubMed Web of Science ®Google Scholar
• Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, et al. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease. Paediatr Int Child Health. 2018;38(3):209–212.
   PubMed Web of Science ®Google Scholar
• Ashouri N, Takahashi M, Dorey F, et al. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr. 2008;153(3):365–368.
   PubMed Web of Science ®Google Scholar
• Rigante D, Valentini P, Rizzo D, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int. 2010;30(6):841–846.
   PubMed Web of Science ®Google Scholar
• Sato S, Kawashima H, Kashiwagi Y, et al. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients. Int J Rheum Dis. 2013;16(2):168–172.
   PubMed Web of Science ®Google Scholar
• Hua W, Sun Y, Wang Y, et al. A new model to predict intravenous immunoglobin-resistant Kawasaki disease. Oncotarget. 2017;8(46):80722–80729.
   PubMedGoogle Scholar
• Lalles JP. Recent advances in intestinal alkaline phosphatase, inflammation, and nutrition. Nutr Rev. 2019;77(10):710–724.
   PubMed Web of Science ®Google Scholar
• Peters E, Geraci S, Heemskerk S, et al. Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate. Br J Pharmacol. 2015;172(20):4932–4945.
   PubMed Web of Science ®Google Scholar
• Wang T, Liu G, Lin H. A machine learning approach to predict intravenous immunoglobulin resistance in kawasaki disease patients: a study based on a southeast China population. PLoS One. 2020;15(8):e0237321.
   PubMed Web of Science ®Google Scholar